These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 3791649)
1. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours. Benker G; Gieshoff B; Freundlieb O; Windeck R; Schulte HM; Lancranjan I; Reinwein D Clin Endocrinol (Oxf); 1986 May; 24(5):505-13. PubMed ID: 3791649 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas. Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499 [TBL] [Abstract][Full Text] [Related]
3. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918 [TBL] [Abstract][Full Text] [Related]
4. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine. Lloyd HM; Jacobi JM; Willgoss DA Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414 [TBL] [Abstract][Full Text] [Related]
6. Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas. Fanghanel G; Larraza O; Villalobos M; Fanghanel L; Velasco M; Velasco F Can J Neurol Sci; 1990 Feb; 17(1):78-82. PubMed ID: 2107017 [TBL] [Abstract][Full Text] [Related]
7. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years. Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897 [TBL] [Abstract][Full Text] [Related]
8. Depot-bromocriptine treatment for prolactinomas and acromegaly. Grossman A; Ross R; Wass JA; Besser GM Clin Endocrinol (Oxf); 1986 Feb; 24(2):231-8. PubMed ID: 3708874 [TBL] [Abstract][Full Text] [Related]
9. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748 [TBL] [Abstract][Full Text] [Related]
10. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas. Lengyel AM; Mussio W; Imamura P; Vieira JG; Lancranjan I Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199 [TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin. Shimatsu A; Murabe H; Nakamura Y; Mizuta H; Ihara C; Nakao K Endocr J; 1999 Feb; 46(1):159-65. PubMed ID: 10426581 [TBL] [Abstract][Full Text] [Related]
12. Secretion of glycoprotein hormone alpha-subunit by pituitary tumors. Ishibashi M; Yamaji T; Takaku F; Teramoto A; Fukushima T J Clin Endocrinol Metab; 1987 Jun; 64(6):1187-93. PubMed ID: 2437140 [TBL] [Abstract][Full Text] [Related]
13. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine. Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262 [TBL] [Abstract][Full Text] [Related]
14. Prolactin secretion in the empty sella syndrome, in prolactinomas and in acromegaly. Brismar K Acta Med Scand; 1981; 209(5):397-405. PubMed ID: 6787839 [TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand. de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343 [TBL] [Abstract][Full Text] [Related]
16. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas. Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021 [TBL] [Abstract][Full Text] [Related]
17. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Wass JA; Moult PJ; Thorner MO; Dacie JE; Charlesworth M; Jones AE; Besser GM Lancet; 1979 Jul; 2(8133):66-9. PubMed ID: 87966 [TBL] [Abstract][Full Text] [Related]
18. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine. Lei T; Bai X; Liu K; Hu W; Xue D; Jiang X J Tongji Med Univ; 1998; 18(3):161-3. PubMed ID: 10806816 [TBL] [Abstract][Full Text] [Related]
19. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. Lamberts SW; de Quijada M; Klijn JG J Endocrinol Invest; 1980; 3(4):343-7. PubMed ID: 7204884 [TBL] [Abstract][Full Text] [Related]
20. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy. Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]